Integral Health Asset Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$38.2M Hold
250,000
1.83% 17
2025
Q4
$34.5M Buy
250,000
+50,000
+25% +$6.55M 1.71% 14
2025
Q3
$25.6M Hold
200,000
1.74% 14
2025
Q2
$24.2M Sell
200,000
-50,000
-20% -$5.64M 2.22% 11
2025
Q1
$27.9M Buy
+250,000
New +$26.6M 2.97% 7
2024
Q4
Sell
-200,000
Closed -$23M 93
2024
Q3
$23M Sell
200,000
-100,000
-33% -$11.3M 2.59% 10
2024
Q2
$31.9M Buy
300,000
+75,000
+33% +$7.53M 3.03% 7
2024
Q1
$21.8M Hold
225,000
2.02% 13
2023
Q4
$22.7M Buy
225,000
+25,000
+13% +$2.41M 3.09% 5
2023
Q3
$20.4M Buy
200,000
+97,000
+94% +$9.85M 2.82% 10
2023
Q2
$10.4M Buy
+103,000
New +$10.3M 1.29% 31
2020
Q2
Sell
-70,000
Closed -$5.77M 76
2020
Q1
$5.77M Buy
+70,000
New +$6.25M 2.54% 15

Other funds holding NVS

Integral Health Asset Management's NVS Position: Q1 2026 in Review

Integral Health Asset Management held its Novartis (NVS) position steady in Q1 2026 at 250,000 shares worth $38.2M. The position accounts for 1.83% of the portfolio, ranked #17.

Integral Health Asset Management first reported a position in NVS in Q1 2020 and has held it in 12 quarters since. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Integral Health Asset Management held 250,000 shares of Novartis worth $38.2M as of Q1 2026.
  • Integral Health Asset Management left its Novartis share count unchanged in Q1 2026.
  • Novartis made up 1.83% of Integral Health Asset Management's portfolio in Q1 2026, its #17 holding.
  • Integral Health Asset Management first reported a position in Novartis in Q1 2020 and has held it in 12 quarters since.
  • 1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Integral Health Asset Management's 13F filing for Q1 2026, filed 15 May 2026.